

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances
NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
equivalents from China
NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced
NEWS 29 APR 03 CAS coverage of exemplified prophetic substances
enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:33:44 ON 06 APR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:33:51 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10551737 R5 aryl all chain bonds.str



chain nodes :

7 10 12 13 14 17 19

ring nodes :

1 2 3 4 5 6 8 11 20

chain bonds :

4-17 5-7 7-8 8-20 10-11 10-20 11-12 12-13 12-14 17-19

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

4-17 5-7 7-8 8-20 10-11 10-20 12-13 12-14 17-19

exact bonds :

11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,S

G2:O,S

G3:Cb,Cy,Hy

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 17:CLASS 19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.48

0.70

FILE 'CAPLUS' ENTERED AT 08:34:06 ON 06 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15

FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 SSS full

REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:34:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 993270 TO ITERATE

99.4% PROCESSED	987139 ITERATIONS	0 ANSWERS
100.0% PROCESSED	993270 ITERATIONS	0 ANSWERS
SEARCH TIME: 00.00.19		

L2 0 SEA SSS FUL L1

L3 0 L2

=> file marpat
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.50	187.58

FULL ESTIMATED COST

FILE 'MARPAT' ENTERED AT 08:34:43 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 150 ISS 13 (20090403/ED)

MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	20090048322	19 FEB 2009
DE	102007039155	19 FEB 2009
EP	2022798	11 FEB 2009
JP	2009035500	19 FEB 2009
WO	2009024087	26 FEB 2009
GB	2451715	11 FEB 2009
FR	2920023	20 FEB 2009
RU	2346937	20 FEB 2009
CA	2618420	24 JAN 2009

The new MARPAT User Guide is now available at:
<http://www.cas.org/support/stngen/stdoc/marpat.html>.

=> s l1 SSS full

FULL SEARCH INITIATED 08:34:46 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 83895 TO ITERATE

73.5% PROCESSED	61691 ITERATIONS	1 ANSWERS
98.2% PROCESSED	82419 ITERATIONS	4 ANSWERS
99.3% PROCESSED	83290 ITERATIONS	4 ANSWERS

100.0% PROCESSED 83895 ITERATIONS
SEARCH TIME: 00.01.01

4 ANSWERS

L4 4 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	131.46	319.04

FILE 'CAPLUS' ENTERED AT 08:35:57 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L4

L5 4 L4

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1090756 CAPLUS Full-text

DOCUMENT NUMBER: 147:406815

TITLE: Preparation of S1P receptor modulating compounds in particular aryl-substituted 2-oxoimidazolidine derivatives as modulator of S1P receptor

INVENTOR(S): Saha, Ashis; Yu, Xiang Y.; Lobera, Mercedes; Lin, Jian; Cheruku, Srinivasa R.; Becker, Oren M.; Marantz, Yael; Schutz, Nili

PATENT ASSIGNEE(S): Epix Delaware, Inc., USA

SOURCE: PCT Int. Appl., 88pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007109330	A2	20070927	WO 2007-US7037	20070321
WO 2007109330	A3	20071122		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007227274	A1	20070927	AU 2007-227274	20070321
CA 2646469	A1	20070927	CA 2007-2646469	20070321
US 20080015177	A1	20080117	US 2007-726356	20070321
EP 2010524	A2	20090107	EP 2007-753647	20070321
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.:

US 2006-784548P P 20060321
WO 2007-US7037 W 20070321

OTHER SOURCE(S): MARPAT 147:406815

GI



AB The invention relates to compds. that have activity as sphingosine-1-phosphate (S1P) receptor modulating agents and the use of such compds. to treat diseases associated with inappropriate S1P receptor activity. Compds. of formula I [A = (un)substituted aryl or heteroaryl; B = N-containing 5- to 6-membered heterocyclyl; X = CO₂H, POH₂, SO₃H, SO₂NH₂, CONHSO₃H and their derivs. or 1H-tetrazol-5-yl; Y = bond or (un)substituted (a)cyclic amine; Z = O, NH and derivs., S, SO, SO₂, SO₂NH and derivs., CO, CS, direct bond, etc.; p and q independently = 0-4], and their pharmaceutically acceptable salts, are prepared and disclosed as modulator of S1P receptor. Thus, e.g., II was prepared by the reaction of Me 4-aminobenzoate with 2-chloroethylisocyanate followed by cyclization to generate intermediate Me 4-(2-oxoimidazolidin-1-yl)benzoate, which underwent condensation with 1-tert-butyl-4-iodobenzene, hydrolysis, reduction and reductive amination with azetidine-3-carboxylic acid to give II. No detailed bioassays and biodata were given.

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:904685 CAPLUS Full-text

DOCUMENT NUMBER: 146:401975

TITLE: Improved process for the preparation of thiotriazolone derivatives useful as antifungal agents

INVENTOR(S): Salman, Mohammad; Sattigeri, Jitendra

PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India

SOURCE: Indian, 15pp.
CODEN: INXXAP

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
IN 193553	A1	20040724	IN 2002-DE457	20020415
PRIORITY APPLN. INFO.:			IN 2002-DE457	20020415
OTHER SOURCE(S):		CASREACT 146:401975; MARPAT 146:401975		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB An improved process for the preparation of thiotriazolone I and its pharmaceutically acceptable salts [Ar = 5-7 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N and S; Ph or a substituted Ph having 1-3 substituents independently selected from halo (e.g. Cl, F, Br or I), NO₂, CN, alkyl, alkoxy, perhaloalkyl or perhaloalkoxy; R₁ and R₂ = H, straight chain or branched alkyl groups having 1 to 3 carbon atoms including Me, Et, Pr or iso-Pr and combinations thereof; Y = CH or N; A = H; (un)substituted alkyl (wherein substituents are selected from halo (F, Cl, Br or I), OH, alkoxy, perhaloalkyl, perhaloalkoxy, unsubstituted or substituted C₅-C₁₀ aromatic or non aromatic rings with or without 1-4 heteroatoms selected independently from C, N and S); etc.] is disclosed. This process comprises converting epoxyalc. II [Ar, R₁, R₂ are defined as above] to the corresponding triflate derivative, which is further subjected to nucleophilic substitution with t-Bu carbazate to afford substituted hydrazine derivative III with inversion of configuration, which is further reacted with compound IV [Y as above] in the presence of a base and polar aprotic solvent at a temperature ranging from 20°C to 120°C to give the epoxide ring opened intermediate V which is then treated with thioisocyanate [ANCS; A as above] in the presence of organic solvent at temperature ranging from 10°C to 90°C to give Boc protected thiosemicarbazide derivs. VI, which is further deprotected in the presence of organic solvent at a temperature in the range of 0°C to 20°C to give free amine VII. The compound VI or its free amine VII is cyclized in the presence of formic acid, tri-Et orthoformate, Et formate/sodium methoxide or formamidine acetate at temperature ranging from 80°C-120°C to give compound I. For example, 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1,2,4-triazol-1-yl)propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl] (2H, 4H)-1,2,4-triazol-3-thione, was prepared starting from the corresponding epoxy alc. II.

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN



ACCESSION NUMBER: 2005:638853 CAPLUS Full-text

DOCUMENT NUMBER: 143:153366

TITLE: Preparation of bicyclic derivatives as PPAR modulators

INVENTOR(S): Conner, Scott Eugene; Mantlo, Nathan Bryan; Zhu, Guoxin; Herr, Robert Jason
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066136	A1	20050721	WO 2004-US39773	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1706386	A1	20061004	EP 2004-812319	20041216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007520471	T	20070726	JP 2006-547017	20041216
US 20070106081	A1	20070510	US 2006-596322	20060609
PRIORITY APPLN. INFO.:			US 2003-532139P	P 20031222
			US 2004-586677P	P 20040709
			WO 2004-US39773	W 20041216
OTHER SOURCE(S):			CASREACT 143:153366; MARPAT 143:153366	
GI				



AB The title compds. I [R1 = H, alkyl, arylalkyl, etc.; R2 = alkyl, heteroalkyl; X = a single bond, O, S, SO2, N; U = an aliphatic linker wherein one carbon atom of the aliphatic linker is optionally replaced with O, NH or S, and wherein such aliphatic linker is optionally substituted with from 1-4 substituents; Y = C, O, S, NH and a single bond; E = CR3R4A or A (wherein A = carboxy, tetrazole, alkyl nitrile, etc.; R3 = H, alkyl, alkoxy; R4 = H, alkyl,, aryloxy, etc.); R8 = H, alkyl, alkenyl, halo; R9 = H, alkyl, halo, etc.; R10,

R11 = H, OH, CN, etc.; R32 = H, halo, alkyl, etc.; AL = fused carbocyclic, fused pyridinyl, fused pyrimidinyl, fused Ph], useful for modulating a peroxisome proliferator activated receptor, were prepared and formulated. E.g., a multi-step synthesis of II, starting from 2-bromo-m-xylene, was given. The binding and cotransfection efficacy values for compds. I which are especially useful for modulating a PPAR receptor, are ≤ 100 nM and $\geq 50\%$, resp.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:638735 CAPLUS Full-text

DOCUMENT NUMBER: 143:153383

TITLE: Preparation of triazole, oxadiazole and thiadiazole derivatives as PPAR modulators for the treatment of diabetes

INVENTOR(S): Mantlo, Nathan Bryan; Navarro, Antonio; Saeed, Ashraf; Gernert, Douglas Linn; Ma, Tianwei; Pfeifer, Lance Allen

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005065683	A1	20050721	WO 2004-US39775	20041221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004311909	A1	20050721	AU 2004-311909	20041221
CA 2549385	A1	20050721	CA 2004-2549385	20041221
EP 1725231	A1	20061129	EP 2004-812321	20041221
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1909902	A	20070207	CN 2004-80038300	20041221
BR 2004017947	A	20070417	BR 2004-17947	20041221
JP 2007515484	T	20070614	JP 2006-547018	20041221
US 20070112045	A1	20070517	US 2006-580202	20060519
US 7507832	B2	20090324		
MX 2006007197	A	20060914	MX 2006-7197	20060622
IN 2006KN01811	A	20070511	IN 2006-KN1811	20060628
PRIORITY APPLN. INFO.:			US 2003-532320P	P 20031222
			US 2004-586563P	P 20040709
			EP 2004-380158	A 20040721
			EP 2004-380159	A 20040721
			EP 2004-350159	A 20040721
			WO 2004-US39775	W 20041221
OTHER SOURCE(S):			CASREACT 143:153383; MARPAT 143:153383	

GI



AB The title compds. I [X = a single bond, O, S, SO₂ and N; U = an aliphatic linker; Y = O, C, S, NH and a single bond; W = N, O or S; E = CR₃R₄A or A (wherein A = carboxy, tetrazole, alkynitrile, carboxamide, sulfonamide and acylsulfonamide; R₃ = H, alkyl, alkoxy; R₄ = H, alkyl, alkoxy, etc.; or R₃ and R₄ are optionally combined to form cycloalkyl); V = (hetero)alkyl, a bond; R₁ = H, alkyl, heteroaryl, etc.; R₈ = H, alkyl, alkenyl, halo; R₉ = H, alkyl, halo, etc.; R₁₀, R₁₁ = H, OH, CN, etc.; R₃₂ = a bond, H, halo, alkyl, etc.] which are modulators of peroxisome proliferator activated receptors (PPARs) and are useful for the treatment of diabetes and other metabolic disorders, were prepared and formulated. E.g., a multi-step synthesis of II, starting from Me glycolate and benzyl bromide, was given. The binding and cotransfection efficacy values for compds. I which are especially useful for modulating a PPAR receptor, are ≤ 100 nM and ≥ 50%, resp.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 08:36:14 ON 06 APR 2009